GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Urologix Inc (OTCPK:ULGX) » Definitions » Degree of Financial Leverage

Urologix (Urologix) Degree of Financial Leverage : 0.00 (As of Mar. 2015)


View and export this data going back to 1996. Start your Free Trial

What is Urologix Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Urologix's Degree of Financial Leverage for the quarter that ended in Mar. 2015 was 0.00. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Urologix's Degree of Financial Leverage or its related term are showing as below:

ULGX's Degree of Financial Leverage is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.98
* Ranked among companies with meaningful Degree of Financial Leverage only.

Urologix Degree of Financial Leverage Historical Data

The historical data trend for Urologix's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Urologix Degree of Financial Leverage Chart

Urologix Annual Data
Trend Jun05 Jun06 Jun07 Jun08 Jun09 Jun10 Jun11 Jun12 Jun13 Jun14
Degree of Financial Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Urologix Quarterly Data
Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Urologix's Degree of Financial Leverage

For the Medical Devices subindustry, Urologix's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Urologix's Degree of Financial Leverage Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Urologix's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Urologix's Degree of Financial Leverage falls into.



Urologix Degree of Financial Leverage Calculation

Urologix's Degree of Financial Leverage for the quarter that ended in Mar. 2015 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -0.23 (Mar. 2015) / -0.25 (Mar. 2014) - 1 )/( -1.018 (Mar. 2015) / -5.401 (Mar. 2014) - 1 )
=-0.08/-0.8115
=0.10***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Urologix  (OTCPK:ULGX) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Urologix Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Urologix's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Urologix (Urologix) Business Description

Traded in Other Exchanges
N/A
Address
14405 21st Avenue North, Suite 110, Minneapolis, MN, USA, 55447
Urologix Inc is a United States-based company engaged in the development, manufacturing, and marketing of minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). The firm markets the Cooled ThermoTherapy (CTC) product line and the Prostiva Radio Frequency (RF) Therapy System (Prostiva). The CTC produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH voiding symptoms. The CTC product line includes the CoolWave and Targis Control Units and the CTC Advance catheter.
Executives
Emery Sidney W Jr director C/O QUALIGEN THERAPEUTICS, INC., 2042 CORTE DEL NOGAL, CARLSBAD CA 92011
Patrick D Spangler director 14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
Gregory Fluet director, officer: CEO 14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
William M Moore director
Guy C Jackson director C/O EPICEPT CORPORATION, 777 OLD SAW MILL ROAD, TARRYTOWN NY 10591
Daniel J Starks director ONE ST JUDE MEDICAL DRIVE, ST PAUL MN 55117
Claude Tihon officer: Chief Technology Officer
Bobby Ivan Griffin director 1326 SPRING VALLEY RD GOLDEN VALLEY PA 55422
David A Montecalvo officer: VP, Product Dev. & Operations 530 HERMAN O. WEST DRIVE, EXTON PA 19341
Susan Bartlett Foote director 649 SUMMIT AVENUE, ST PAUL MN 55105

Urologix (Urologix) Headlines

From GuruFocus

Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 16,900 Shares

By GuruFocus Research GuruFocus Editor 12-09-2009

Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 3,100 Shares

By GuruFocus Research GuruFocus Editor 12-07-2009

Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 5,200 Shares

By GuruFocus Research GuruFocus Editor 02-01-2011

Urologix Inc. Reports Operating Results (10-K)

By gurufocus 10qk 09-21-2009

Urologix Inc. Reports Operating Results (10-K)

By gurufocus 10qk 09-17-2010